Report Information More information from: https ://www.wis eguyreports .com/reports /495867
Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2016 Report / Search Code: WGR495867
Price
1-user P DF : $ 2000.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 4000.0
Enterprise P DF : $ 6000.0
Gas trointes tinal Stromal Tumor (GIST) - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Gas trointes tinal Stromal Tumor (GIST) - Pipeline Review, H1 2016’, provides an overview of the Gas trointes tinal Stromal Tumor (GIST) pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for Gas trointes tinal Stromal Tumor (GIST), complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in therapeutic development for Gas trointes tinal Stromal Tumor (GIST) and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape of Gas trointes tinal Stromal Tumor (GIST) - The report reviews pipeline therapeutics for Gas trointes tinal Stromal Tumor (GIST) by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved Gas trointes tinal Stromal Tumor (GIST) therapeutics and enlis ts all their major and minor projects - The report as s es s es Gas trointes tinal Stromal Tumor (GIST) therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news related to pipeline therapeutics for Gas trointes tinal Stromal Tumor (GIST) Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for Gas trointes tinal Stromal Tumor (GIST) - Identify potential new clients or partners in the target demographic
- Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding Gas trointes tinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents:
Table of Contents Table of Contents 2 Lis t of Tables 7 Lis t of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Gas trointes tinal Stromal Tumor (GIST) Overview 10 Therapeutics Development 11 Pipeline Products for Gas trointes tinal Stromal Tumor (GIST) - Overview 11 Pipeline Products for Gas trointes tinal Stromal Tumor (GIST) - Comparative Analys is 12 Gas trointes tinal Stromal Tumor (GIST) - Therapeutics under Development by Companies 13 Gas trointes tinal Stromal Tumor (GIST) - Therapeutics under Inves tigation by Univers ities /Ins titutes 15 Gas trointes tinal Stromal Tumor (GIST) - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Gas trointes tinal Stromal Tumor (GIST) - Products under Development by Companies 19 Gas trointes tinal Stromal Tumor (GIST) - Products under Inves tigation by Univers ities /Ins titutes 21 Gas trointes tinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development 22 AB Science SA 22 Advenchen Laboratories , LLC 23 Ariad Pharmaceuticals , Inc. 24 Arog Pharmaceuticals , Inc. 25 Array BioPharma Inc. 26 As tex Pharmaceuticals , Inc. 27 Blueprint Medicines Corporation 28 Bos ton Biomedical, Inc. 29 Calithera Bios ciences , Inc. 30 Chips creen Bios ciences Ltd 31 Deciphera Pharmaceuticals , LLC 32 F. Hoffmann-La Roche Ltd. 33 Horizon Pharma Plc 34 Immunicum AB 35 Jiangs u Hengrui Medicine Co., Ltd. 36 Kolltan Pharmaceuticals , Inc. 37 Natco Pharma Limited 38 Nerviano Medical Sciences S.r.l. 39 Novartis AG 40 Omeros Corporation 41 Plexxikon Inc. 42 TG Therapeutics , Inc. 43 Thres hold Pharmaceuticals , Inc. 44 Gas trointes tinal Stromal Tumor (GIST) - Therapeutics As s es s ment 45 As s es s ment by Monotherapy Products 45 As s es s ment by Combination Products 46 As s es s ment by Target 47 As s es s ment by Mechanis m of Action 50 As s es s ment by Route of Adminis tration 53 As s es s ment by Molecule Type 55 Drug Profiles 57 alpelis ib - Drug Profile 57 Product Des cription 57 Mechanis m of Action 57 R& D Progres s 57 apatinib - Drug Profile 59 Product Des cription 59 Mechanis m of Action 59 R& D Progres s 59
BB-503 - Drug Profile 62 Product Des cription 62 Mechanis m of Action 62 R& D Progres s 62 binimetinib - Drug Profile 64 Product Des cription 64 Mechanis m of Action 64 R& D Progres s 64 BLU-285 - Drug Profile 69 Product Des cription 69 Mechanis m of Action 69 R& D Progres s 69 buparlis ib hydrochloride - Drug Profile 70 Product Des cription 70 Mechanis m of Action 70 R& D Progres s 70 CB-839 - Drug Profile 74 Product Des cription 74 Mechanis m of Action 74 R& D Progres s 74 CHMFLKIT-110 - Drug Profile 76 Product Des cription 76 Mechanis m of Action 76 R& D Progres s 76 crenolanib bes ylate - Drug Profile 77 Product Des cription 77 Mechanis m of Action 77 R& D Progres s 77 CS-2164 - Drug Profile 79 Product Des cription 79 Mechanis m of Action 79 R& D Progres s 79 dabrafenib mes ylate + trametinib dimethyl s ulfoxide - Drug Profile 80 Product Des cription 80 Mechanis m of Action 80 R& D Progres s 80 DCC-2618 - Drug Profile 83 Product Des cription 83 Mechanis m of Action 83 R& D Progres s 83 evofos famide - Drug Profile 84 Product Des cription 84 Mechanis m of Action 84 R& D Progres s 84 infigratinib - Drug Profile 91 Product Des cription 91 Mechanis m of Action 91 R& D Progres s 91 interferon gamma-1b - Drug Profile 93 Product Des cription 93 Mechanis m of Action 93 R& D Progres s 93 Intuvax - Drug Profile 96 Product Des cription 96 Mechanis m of Action 96 R& D Progres s 96 KTN-0158 - Drug Profile 100 Product Des cription 100 Mechanis m of Action 100 R& D Progres s 100 mas itinib - Drug Profile 102 Product Des cription 102 Mechanis m of Action 102 R& D Progres s 102 nilotinib - Drug Profile 108 Product Des cription 108 Mechanis m of Action 108 R& D Progres s 108 NMSP-088 - Drug Profile 112 Product Des cription 112 Mechanis m of Action 112 R& D Progres s 112 NRCAN-019 - Drug Profile 113 Product Des cription 113 Mechanis m of Action 113 R& D Progres s 113 onales pib - Drug Profile 115 Product Des cription 115
Mechanis m of Action 115 R& D Progres s 115 pexidartinib - Drug Profile 118 Product Des cription 118 Mechanis m of Action 118 R& D Progres s 118 PLX-9486 - Drug Profile 120 Product Des cription 120 Mechanis m of Action 120 R& D Progres s 120 ponatinib hydrochloride - Drug Profile 121 Product Des cription 121 Mechanis m of Action 121 R& D Progres s 121 SF-1126 - Drug Profile 124 Product Des cription 124 Mechanis m of Action 124 R& D Progres s 124 SHR-1020 - Drug Profile 126 Product Des cription 126 Mechanis m of Action 126 R& D Progres s 126 Small Molecule to Antagonize GPR20 for Gas tro-Intes tinal Stromal Tumors and Acute Myeloid Leukemia - Drug Profile 128 Product Des cription 128 Mechanis m of Action 128 R& D Progres s 128 Small Molecules to Inhibit c-Kit for Gas trointes tinal Stromal Tumor - Drug Profile 129 Product Des cription 129 Mechanis m of Action 129 R& D Progres s 129 TGR-1202 - Drug Profile 130 Product Des cription 130 Mechanis m of Action 130 R& D Progres s 130 vemurafenib - Drug Profile 133 Product Des cription 133 Mechanis m of Action 133 R& D Progres s 133 Gas trointes tinal Stromal Tumor (GIST) - Recent Pipeline Updates 137 Gas trointes tinal Stromal Tumor (GIST) - Dormant Projects 198 Gas trointes tinal Stromal Tumor (GIST) - Dis continued Products 199 Gas trointes tinal Stromal Tumor (GIST) - Product Development Miles tones 200 Featured News & Pres s Releas es 200 Apr 20, 2016: Kolltan Pharmaceuticals Announces Pres entations of Anti-KIT Antibody Preclinical Data at the 2016 American As s ociation for Cancer Res earch Annual Meeting 200 Jul 13, 2015: Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for BLU-285 201 Apr 19, 2015: Blueprint Medicines Pres ents New Preclinical Data Demons trating Significant Anti-Tumor Activity of BLU-285 in Treatment-Res is tant GIST and on Novel Cancer Drug Targets 201 Apr 08, 2015: Blueprint Medicines to Pres ent New Preclinical Data on BLU-285 in Treatment-Res is tant GIST and on Novel Cancer Drug Targets at Upcoming AACR Annual Meeting 202 Jun 01, 2014: ARIAD Announces Initial Data from Phas e 2 Trial of Ponatinib in Patients with Gas trointes tinal Stromal Tumors 202 Mar 20, 2014: CHMP Adopts Negative Opinion For AB Science's Mas ican 203 Oct 09, 2013: ARIAD Announces Changes in the Clinical Development Program of Iclus ig 204 Jun 11, 2013: Ariad Pharma Initiates Phas e II Trial Of Ponatinib In Patients With Gas trointes tinal Stromal Tumors 205 Jun 02, 2013: Thres hold Pharma Announces Data From Two Ongoing Phas e I/II Trials Of TH-302 At 2013 ASCO Annual Meeting 206 Apr 09, 2013: Ariad Pharma Pres ents New Preclinical Data Showing Ponatinib Overcomes Res is tant Mutations In Oncogenic Driver Of Gas trointes tinal Stromal Tumors 207 Appendix 208 Methodology 208 Coverage 208 Secondary Res earch 208 Primary Res earch 208 Expert Panel Validation 208 Contact Us 208 Dis claimer 209 Lis t of Tables Number of Products under Development for Gas trointes tinal Stromal Tumor (GIST), H1 2016 11
Number of Products under Development for Gas trointes tinal Stromal Tumor (GIST) Comparative Analys is , H1 2016 12 Number of Products under Development by Companies , H1 2016 14 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 15 Comparative Analys is by Late Stage Development, H1 2016 16 Comparative Analys is by Clinical Stage Development, H1 2016 17 Comparative Analys is by Early Stage Development, H1 2016 18 Products under Development by Companies , H1 2016 19 Products under Development by Companies , H1 2016 (Contd..1) 20 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 21 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H1 2016 22 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories , LLC, H1 2016 23 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals , Inc., H1 2016 24 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals , Inc., H1 2016 25 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc., H1 2016 26 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by As tex Pharmaceuticals , Inc., H1 2016 27 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corporation, H1 2016 28 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Bos ton Biomedical, Inc., H1 2016 29 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Calithera Bios ciences , Inc., H1 2016 30 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Chips creen Bios ciences Ltd, H1 2016 31 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals , LLC, H1 2016 32 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by F. Homann-La Roche Ltd., H1 2016 33 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Horizon Pharma Plc, H1 2016 34 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H1 2016 35 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Jiangs u Hengrui Medicine Co., Ltd., H1 2016 36 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Kolltan Pharmaceuticals , Inc., H1 2016 37 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Limited, H1 2016 38 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences S.r.l., H1 2016 39 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H1 2016 40 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Omeros Corporation, H1 2016 41 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc., H1 2016 42 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by TG Therapeutics , Inc., H1 2016 43 Gas trointes tinal Stromal Tumor (GIST) - Pipeline by Thres hold Pharmaceuticals , Inc., H1 2016 44 As s es s ment by Monotherapy Products , H1 2016 45 As s es s ment by Combination Products , H1 2016 46 Number of Products by Stage and Target, H1 2016 48 Number of Products by Stage and Mechanis m of Action, H1 2016 51 Number of Products by Stage and Route of Adminis tration, H1 2016 54 Number of Products by Stage and Molecule Type, H1 2016 56 Gas trointes tinal Stromal Tumor (GIST) Therapeutics - Recent Pipeline Updates , H1 2016 137 Gas trointes tinal Stromal Tumor (GIST) - Dormant Projects , H1 2016 198 Gas trointes tinal Stromal Tumor (GIST) - Dis continued Products , H1 2016 199 Lis t of Figures Number of Products under Development for Gas trointes tinal Stromal Tumor (GIST), H1 2016 11 Number of Products under Development for Gas trointes tinal Stromal Tumor (GIST) Comparative Analys is , H1 2016 12 Number of Products under Development by Companies , H1 2016 13 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 15 Comparative Analys is by Late Stage Development, H1 2016 16 Comparative Analys is by Clinical Stage Development, H1 2016 17 Comparative Analys is by Early Stage Products , H1 2016 18 As s es s ment by Monotherapy Products , H1 2016 45 Number of Products by Top 10 Targets , H1 2016 47 Number of Products by Stage and Top 10 Targets , H1 2016 47 Number of Products by Top 10 Mechanis m of Actions , H1 2016 50 Number of Products by Stage and Top 10 Mechanis m of Actions , H1 2016 50 Number of Products by Routes of Adminis tration, H1 2016 53 Number of Products by Stage and Routes of Adminis tration, H1 2016 53
Number of Products by Molecule Types , H1 2016 55 Number of Products by Stage and Molecule Types , H1 2016 55
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349